ALIAS (Albumin in Acute Ischemic Stroke) Trials: Analysis of the Combined Data From Parts 1 and 2 [Clinical Sciences]

Conclusions— Treatment with intravenous albumin 25% at 2 g/kg was not associated with improved outcome at 90 days and was associated with increased rates of intracerebral hemorrhage and pulmonary edema. Clinical Trial Registration— URL: https://www.clinicaltrials.gov. Unique identifier: NCT00235495.
Source: Stroke - Category: Neurology Authors: Tags: Clinical Studies, Ischemic Stroke Clinical Sciences Source Type: research